Sandbox g19: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
mNo edit summary
Line 48: Line 48:
:::* Preferred regimen
:::* Preferred regimen
::::* [[Isoniazid]] 300 mg qd {{and}} [[Rifampin]] 600 mg qd {{and}} [[Pyrazinamide]] 15–30 mg qd {{and}} [[Ethambutol]] 15 mg/kg/day qd
::::* [[Isoniazid]] 300 mg qd {{and}} [[Rifampin]] 600 mg qd {{and}} [[Pyrazinamide]] 15–30 mg qd {{and}} [[Ethambutol]] 15 mg/kg/day qd
* Pathogen-directed antimicrobial therapy
:* Bacteria
::* Actinomyces
:::* Preferred regimen
::::* [[Penicillin G]] 24 MU q4h
::* Bacteroides fragilis
:::* Preferred regimen
::::* [[Metronidazole]] 30 mg/kg/day q6h
::* Enterobacteriaceae
:::* Preferred regimen
::::* [[Cefotaxime]] 8–12 g/day q4–6h {{or}} [[Ceftriaxone]] 4 g/day q12h
::* Fusobacterium
:::* Preferred regimen
::::* [[Metronidazole]] 30 mg/kg/day q6h
::* Haemophilus
:::* Preferred regimen
::::* [[Cefotaxime]] 8–12 g/day q4–6h {{or}} [[Ceftriaxone]] 4 g/day q12h
::* Listeria monocytogenes
:::* Preferred regimen
::::* [[Ampicillin]] 12 g/day q4h {{or}} [[Penicillin G]] 24 MU q4h
::* Nocardia
:::* Preferred regimen
::::* [[TMP-SMZ]] 10–20 mg/kg/day q6–12h {{or}} [[Sulfadiazine]] 4–6 g/day q6h
::* Prevotella melaninogenica
:::* Preferred regimen
::::* [[Metronidazole]] 30 mg/kg/day q6h
::* Pseudomonas aeruginosa
:::* Preferred regimen
::::* [[Ceftazidime]] 6 g/day q8h {{or}} [[Cefepime]] 6 g/day q8h
::* Methicillin-sensitive Staphylococcus aureus
:::* Preferred regimen
::::* [[Nafcillin]] 12 g/day q4h {{or}} [[Oxacillin]] 12 g/day q4h
::* Methicillin-resistant Staphylococcus aureus
:::* Preferred regimen
::::* [[Vancomycin]] 30–45 mg/kg/day q8–12h
::* Streptococcus anginosus and other streptococci
:::* Preferred regimen
::::* [[Penicillin G]] 24 MU q4h

Revision as of 05:13, 5 June 2015

Brain abscess

  • Empiric antimicrobial therapy
  • Brain abscess in otherwise healthy patients
  • Preferred regimen
  • Alternative regimen
  • Brain abscess with comorbidities
  • Otitis media, mastoiditis, or sinusitis
  • Preferred regimen
  • Dental infection
  • Preferred regimen
  • Penetrating trauma or post-neurosurgy
  • Preferred regimen
  • Lung abscess, empyema, or bronchiectasis
  • Preferred regimen
  • Bacterial endocarditis
  • Preferred regimen
  • Congenital heart disease
  • Preferred regimen
  • Transplant recipients
  • Preferred regimen
  • Patients with HIV/AIDS
  • Preferred regimen
  • Staphylococcus aureus coverage
  • Preferred regimen
  • Mycobacterium tuberculosis coverage
  • Preferred regimen
  • Pathogen-directed antimicrobial therapy
  • Bacteria
  • Actinomyces
  • Preferred regimen
  • Bacteroides fragilis
  • Preferred regimen
  • Enterobacteriaceae
  • Preferred regimen
  • Fusobacterium
  • Preferred regimen
  • Haemophilus
  • Preferred regimen
  • Listeria monocytogenes
  • Preferred regimen
  • Nocardia
  • Preferred regimen
  • Prevotella melaninogenica
  • Preferred regimen
  • Pseudomonas aeruginosa
  • Preferred regimen
  • Methicillin-sensitive Staphylococcus aureus
  • Preferred regimen
  • Methicillin-resistant Staphylococcus aureus
  • Preferred regimen
  • Streptococcus anginosus and other streptococci
  • Preferred regimen